RxDoctor Payments DataLook up a doctor →

William Wagner, MD

Neurology · Louisville, CONPI 1598738155

Payments from drug & device makers

$1,504,112in general payments, 2019–2025

Across 585 payments — averaging $2571.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.5M
  • Sanofi$14K
  • EMD Serono, Inc.$774
  • AbbVie$678
  • Amgen$556
  • MDD US Operations, LLC$546
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$2,95513%
  • Speaking & faculty fees$10,01245%
  • Travel & lodging$7353%
  • Food & beverage$8,38438%
  • Education$1521%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,504,112 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$62,549
Medicare patients
218
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab11$111,850
Carbidopa-LevodopaCarbidopa/Levodopa68$1,881
Oxcarbazepine20$1,652
Gabapentin115$1,632
Memantine Hcl43$1,340
Pregabalin55$1,090
Primidone38$921
Lamotrigine34$881
Rasagiline Mesylate16$866
Teriflunomide19$732
Levetiracetam22$584
Topiramate46$529
Donepezil Hcl46$519
Propranolol Hcl ErPropranolol Hcl11$416
Propranolol Hcl35$391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$34$52946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 neurology providers in Colorado.

Other neurology in Louisville

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →